Webb spoke with Becker's about how Intermountain overcame these obstacles to roll out a successful antibody treatment program that's reached at least 1,000 patients, alongside a research effort to better understand real-world efficacy.Įditor's note: Responses have been edited for length and clarity. What's more, infusion centers typically treat patients with cancer or autoimmune diseases who have suppressed immune systems, so bringing actively contagious COVID-19 patients to these settings for antibody treatment also poses infection control hurdles.ĭr. "That's a long time to have someone in a devoted space where they need to have nursing resources and supervision," said Brandon Webb, MD, an infectious disease physician at Salt Lake City-based Intermountain Healthcare. The treatment entails a one-hour infusion followed by a one-hour monitoring period that must be performed in healthcare settings capable of managing an anaphylactic reaction in the rare instance it occurs. While the FDA granted emergency use authorization to Regeneron and Eli Lilly's antibody treatments in November 2020, many healthcare organizations have been slow to adopt these treatments due to a web of logistical challenges. 50 community hospital cfos to know | 2022.83 community hospital ceros to know | 2022.260+ healthcare revenue cycle management companies to know | 2022.50 chief digital officer innovators to know | 2022.75 black healthcare leaders to know| 2022.150 top places to work in healthcare | 2022.Past Issues - Becker's Clinical Leadership & Infection Control.Current Issue - Becker's Clinical Leadership & Infection Control.Becker's Cardiology + Heart Surgery Podcast. Becker's Ambulatory Surgery Centers Podcast.Becker’s Digital Health + Health IT Podcast.LeanTaaS Transform Hospital Operations Virtual Summit.20th Annual Spine, Orthopedic & Pain Management-Driven ASC Conference.Clinical Leadership & Infection Control.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |